Relevant bibliographies by topics / Kosac regiments

Contents

  1. Journal articles
  2. Dissertations / Theses

Academic literature on the topic 'Kosac regiments'

Author: Grafiati
Published: 28 May 2022
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Kosac regiments.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Kosac regiments"

1

Kim, Dong-Sool. "Air Pollution History, Regulatory Changes, and Remedial Measures of the Current Regulatory Regimes in Korea." Journal of Korean Society for Atmospheric Environment 29, no. 4 (2013): 353–68. http://dx.doi.org/10.5572/kosae.2013.29.4.353.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Mitsiades, Constantine S., Michele Agler, YingJie Zhu, et al. "Effects of Tanespimycin On Glucocorticoid Receptor Translocation." Blood 114, no. 22 (2009): 4921. http://dx.doi.org/10.1182/blood.v114.22.4921.4921.

Full text
Abstract:
Abstract Abstract 4921 INTRODUCTION Tanespimycin (BMS-722782) exhibits antitumor activity in diverse models of hematologic malignancies and solid tumors by suppressing the chaperoning activity of heat shock protein 90 (Hsp90) including its ability to preserve the proper three-dimensional structure and intracellular trafficking of its client proteins. However, not all potential client proteins are affected to the same degree by Hsp90 inhibitors. Tanespimycin is in phase 3 clinical development with bortezomib for the treatment of multiple myeloma (MM). Because glucocorticoids form the backbone o
APA, Harvard, Vancouver, ISO, and other styles
3

Mitsiades, Constantine S. "How to Overcome Myeloma Stem Cell Resistance to Therapy - Targeting the Stem Cell Niche." Blood 116, no. 21 (2010): SCI—6—SCI—6. http://dx.doi.org/10.1182/blood.v116.21.sci-6.sci-6.

Full text
Abstract:
Abstract Abstract SCI-6 The concept of cancer stem cells has attracted again intense research interest, as the drug resistance attributed to this infrequent subpopulation of tumor cells could explain how patients can relapse even after prolonged complete clinical, biochemical, radiologic or even molecular remissions. In multiple myeloma (MM), several aspects of the cancer stem cell concept remain to be elucidated, including the potential heterogeneity of this cell subpopulation or whether CD138+ expression is incompatible or not with a MM stem cell. As these questions are being resolved, emerg
APA, Harvard, Vancouver, ISO, and other styles
4

Jakubikova, Jana, Melissa Ooi, Steffen Klippel, et al. "Synergistic Enhancement of Conventional Anti-MM Drugs Efficacy with Plant Isothiocyanates: Therapeutic Implications." Blood 116, no. 21 (2010): 5016. http://dx.doi.org/10.1182/blood.v116.21.5016.5016.

Full text
Abstract:
Abstract Abstract 5016 Introduction: Multiple myeloma (MM) is a hematologic malignancy characterized by an abundant clonal proliferation of plasma cells in the bone marrow. Despite significant recent progress in the treatment of MM, this plasma cell dyscrasia remains incurable. Therefore, the pursuit of new investigational therapeutic agents, used alone or in combination is critically important to improve patient outcome. In our previous studies, we introduced plant isothiocyanates (ITCs) as compounds with potent cytotoxicity against MM cell lines and primary MM samples. The effect of these co
APA, Harvard, Vancouver, ISO, and other styles
5

Jakubikova, Jana, David N. Cervi, John F. Daley, et al. "Targeting the Clonogenic Side Population of Multiple Myeloma by Immunomodulatory Drugs (IMiDs) in the Context of Stromal Cell Microenvironment: Pathophysiologic and Clinical Implications." Blood 114, no. 22 (2009): 954. http://dx.doi.org/10.1182/blood.v114.22.954.954.

Full text
Abstract:
Abstract Abstract 954 Introduction: Multiple myeloma (MM), a malignancy of plasma cells, remains incurable even though newly established regimens incorporating conventional and novel agents are capable of achieving complete clinical and biochemical remissions in a sizeable subset of MM patients. This indicates the presence of a distinctive drug-resistant sub-population of MM cells, which might be responsible for tumor re-growth. Methods and Results: To evaluate this phenomenon, we performed flow cytometry-based Hoechst 33342 staining assay to evaluate the existence and characteristics in MM of
APA, Harvard, Vancouver, ISO, and other styles
6

Hayes, *Catriona A., *Paul Dowling, Joseph Negri, et al. "Proteomic Characterization of An Isogenic Multiple Myeloma Cell Line Model of Bortezomib Resistance." Blood 118, no. 21 (2011): 1820. http://dx.doi.org/10.1182/blood.v118.21.1820.1820.

Full text
Abstract:
Abstract Abstract 1820 Proteasome inhibitors such as Bortezomib (Bort) represent a key drug class for the therapeutic management of multiple myeloma (MM). However, MM patients, even those who initially achieve complete clinical and biochemical remission with bortezomib-based regimens eventually relapse, and bortezomib-refractory disease is associated with short overall survival. Identifying the molecular basis of resistance to bortezomib is therefore crucial for the rational development of novel therapies to hopefully improve clinical outcome for advanced MM. To address this question, we gener
APA, Harvard, Vancouver, ISO, and other styles
7

Delmore, Jake, David N. Cervi, Douglas McMillin, et al. "The Transcriptional Signature of Kinases Inhibited by the Multi-Targeted Kinase Inhibitor AS703569 Is Associated with Clinical Outcome in Multiple Myeloma (MM): Anti-MM Activity of AS703569 in Preclinical Studies." Blood 114, no. 22 (2009): 730. http://dx.doi.org/10.1182/blood.v114.22.730.730.

Full text
Abstract:
Abstract Abstract 730 Multi-targeted kinase inhibitors, when associated with manageable toxicity, offer the therapeutically desirable option of targeting, through a single chemical entity, several pathways that may contribute to the complexity and heterogeneity of molecular lesions harbored by neoplasias such as multiple myeloma (MM). However, intractable questions often emerge while prioritizing for preclinical studies different multi-targeted agents with extensive and/or only partially overlapping of sets of known targets. We have hypothesized that the potential therapeutic relevance of a mu
APA, Harvard, Vancouver, ISO, and other styles
8

Richardson, Paul, Donna Weber, Constantine S. Mitsiades, et al. "A Phase I Study of Vorinostat, Lenalidomide, and Dexamethasone In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Excellent Tolerability and Promising Activity In a Heavily Pretreated Population." Blood 116, no. 21 (2010): 1951. http://dx.doi.org/10.1182/blood.v116.21.1951.1951.

Full text
Abstract:
Abstract Abstract 1951 Background: Although novel treatment combinations for multiple myeloma (MM) have improved outcomes, the disease remains incurable and new drug combinations are urgently needed. Vorinostat is an oral histone deacetylase inhibitor approved in the United States for treatment of patients (pts) with advanced cutaneous T-cell lymphoma who failed prior therapies. Vorinostat alters gene expression and protein activity, promoting MM cell death through multiple pathways, and has been shown in preclinical studies to synergistically enhance the anti-MM activity of bortezomib and imm
APA, Harvard, Vancouver, ISO, and other styles

Dissertations / Theses on the topic "Kosac regiments"

1

Семенов, Володимир Миколайович, Владимир Николаевич Семенов та Volodymyr Mykolaiovych Semenov. "Заселення Слобідської України як досвід українсько-російської взаємодії". Thesis, Видавництво СумДУ, 2010. http://essuir.sumdu.edu.ua/handle/123456789/3826.

Full text
Abstract:
У статті розглянуто історичний досвід взаємодії українського та російського етносів у процесі заселення Слобідської України у другій половині XVII – на початку XVIII ст. При цитуванні документа, використовуйте посилання http://essuir.sumdu.edu.ua/handle/123456789/3826<br>In this article the historical experience of cooperation between the Ukrainian and Russian nations during the moving into the Slobidska Ukraine at the second half of the XVII – the beginning of the XVIII cent. is described. При цитировании документа, используйте ссылку http://essuir.sumdu.edu.ua/handle/123456789/3826
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography